Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

API Import to Russia (June and First Half of 2020)

Monday, July 27, 2020

Between January and June 2020, Russia imported 87.3 bln RUB worth of APIs (customs clearance and VAT included), which is in monetary terms (rubles) 54% higher than in 2019. In physical terms, the import volume amounted to 7.3 thousand tons of APIs, including commercial ones, with the dynamics of +25%.

The import structure has undergone significant changes. Commercial APIs accounted for 3.4% of the import in monetary terms (against 4.8% in 2019) and for 4.6% in physical terms (3.4% in 2019).

As for the importing countries, Malaysia, Mexico, and Macao have the best dynamics (imports grown by 12.9, 6.4, and 4.4 times, respectively). While those countries are not new on the list, this year they have become many times more important. However, those countries import very few APIs; Dexamethasonum, Betamethasonum, and Methylprednisolone from Malaysia, Clavulanate Potassium + Сellulose Microcristallic, Rifaximinum, Tribromphenate Bismuth and Phosphomycinum from Mexico, and Doxycyclinum from Macao. Only Japan has comparable dynamics – +650% in monetary and -42% in physical terms – mainly due to changes in the import line. The import of more or less inexpensive APIs (Glycinum, Sevofluranum, Benphothiaminum) has either stopped or fallen, while the import of expensive APIs has multiplied. In particular, the import of Dolutegravirum has risen by 10 times in monetary and by 12 times in physical terms. KRKA-Rus has the highest import volume in monetary terms among the importing companies (import grown by 1.8 times). KRKA-Rus is followed by last year’s leader Servier, with the dynamics of -13%.

AstraZeneca Industries has the best dynamics (by 36.3 times in monetary terms), while importing only two APIs: Dapagliflozinum and Ticagrelorum. Full-cycle production of the corresponding pharmaceutical drugs (Forxiga and Brilinta) has been localized at the company’s facilities in the Kaluga Region. Biocom comes second, its imports have grown by nearly 17 times. Hydroxychlorochinum contributed to the dynamics the most due to an increased demand because of the pandemic.

Dynamics of pharmacopoeial and commercial API import to Russia (EEU countries excluded), free circulation prices including customs clearance and VAT (2016 – 2019, January – June 2020)